Orthocell's strategic international expansion

Orthocell (ASX:OCC), a regenerative medicine company, is expanding into Singapore by appointing Device Technologies Asia as the exclusive distributor for its nerve repair device, Remplir™. This expansion is set to begin with anticipated sales in the first quarter of CY25.

Orthocell's growth and future plans

Orthocell is strengthening its international presence by launching its nerve repair device, Remplir™, in Singapore, marking its first major market entry outside Australasia. Partnering with Device Technologies Asia, Orthocell aims for initial sales in Q1 CY25. Singapore is a strategic hub for advanced medical treatments and offers pathways to other ASEAN markets. With a strong financial position and ongoing regulatory programs, Orthocell plans to expand further into the US and other global markets, leveraging its innovative product portfolio to drive growth and revenue.

Executive insights on Singapore expansion

We are excited to extend our partnership with Device Technologies Asia to Singapore, a key strategic market for our global growth. Remplir has shown significant success in Australia and New Zealand, and we are confident in capturing similar market penetration in Singapore,' said Paul Anderson, CEO and MD of Orthocell.